Renaissance Technologies LLC acquired a new position in shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,402,589 shares of the specialty pharmaceutical company’s stock, valued at approximately $41,574,000. Renaissance Technologies LLC owned 0.69% of Valeant Pharmaceuticals International as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Valeant Pharmaceuticals International by 2.9% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 490,395 shares of the specialty pharmaceutical company’s stock valued at $8,509,000 after purchasing an additional 13,810 shares in the last quarter. Morgan Stanley grew its position in shares of Valeant Pharmaceuticals International by 48.2% in the first quarter. Morgan Stanley now owns 2,777,063 shares of the specialty pharmaceutical company’s stock valued at $30,631,000 after purchasing an additional 903,256 shares during the period. Raymond James Financial Services Advisors Inc. grew its position in shares of Valeant Pharmaceuticals International by 61.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 41,414 shares of the specialty pharmaceutical company’s stock valued at $457,000 after purchasing an additional 15,719 shares during the period. Legal & General Group Plc grew its position in shares of Valeant Pharmaceuticals International by 9.2% in the second quarter. Legal & General Group Plc now owns 1,435,670 shares of the specialty pharmaceutical company’s stock valued at $23,895,000 after purchasing an additional 121,032 shares during the period. Finally, Bogle Investment Management L P DE acquired a new stake in shares of Valeant Pharmaceuticals International in the first quarter valued at about $11,223,000. Institutional investors own 50.48% of the company’s stock.

Several equities research analysts recently issued reports on VRX shares. J P Morgan Chase & Co set a $10.00 price objective on Valeant Pharmaceuticals International and gave the stock a “hold” rating in a report on Monday, July 17th. Cantor Fitzgerald reissued a “buy” rating and set a $23.00 target price on shares of Valeant Pharmaceuticals International in a report on Tuesday, August 29th. Guggenheim started coverage on Valeant Pharmaceuticals International in a report on Saturday, June 17th. They set a “buy” rating and a $18.00 target price for the company. Wells Fargo & Company restated an “underperform” rating and issued a $9.00 target price on shares of Valeant Pharmaceuticals International in a research report on Thursday, August 10th. Finally, Deutsche Bank AG set a $19.00 target price on Valeant Pharmaceuticals International and gave the company a “hold” rating in a research report on Monday, August 21st. Five analysts have rated the stock with a sell rating, thirteen have given a hold rating and five have given a buy rating to the company’s stock. Valeant Pharmaceuticals International currently has an average rating of “Hold” and a consensus target price of $17.57.

TRADEMARK VIOLATION WARNING: This piece was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/2402589-shares-in-valeant-pharmaceuticals-international-inc-vrx-acquired-by-renaissance-technologies-llc/1605214.html.

In related news, Director Schutter Richard U. De bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The shares were acquired at an average cost of $14.33 per share, with a total value of $143,300.00. Following the completion of the transaction, the director now owns 77,479 shares of the company’s stock, valued at $1,110,274.07. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 5.87% of the company’s stock.

Shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) opened at 14.62 on Tuesday. The company has a 50-day moving average of $13.97 and a 200 day moving average of $13.35. The firm’s market cap is $5.10 billion. Valeant Pharmaceuticals International, Inc. has a 12-month low of $8.31 and a 12-month high of $24.89.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The company had revenue of $2.23 billion during the quarter, compared to the consensus estimate of $2.23 billion. During the same quarter in the prior year, the company posted ($0.88) EPS. The company’s quarterly revenue was down 7.7% compared to the same quarter last year. Equities research analysts anticipate that Valeant Pharmaceuticals International, Inc. will post $3.89 earnings per share for the current fiscal year.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.